Show simple item record

dc.contributor.authorBrothwell, M
dc.contributor.authorWest, Catharine ML
dc.contributor.authorDunning, A
dc.contributor.authorBurnet, Neil G
dc.contributor.authorBarnett, G
dc.date.accessioned2019-04-29T09:48:57Z
dc.date.available2019-04-29T09:48:57Z
dc.date.issued2019en
dc.identifier.citationBrothwell MRS, West CM, Dunning AM, Burnet NG, Barnett GC. Radiogenomics in the era of advanced radiotherapy. Clin Oncol. 2019 May;31(5):319-25.en
dc.identifier.pmid30914148en
dc.identifier.doi10.1016/j.clon.2019.02.006en
dc.identifier.urihttp://hdl.handle.net/10541/621769
dc.description.abstractMost radiogenomics studies investigate how genetic variation can help to explain the differences in early and late radiotherapy toxicity between individuals. The field of radiogenomics in photon beam therapy has grown rapidly in recent years, carving out a unique translational discipline, which has progressed from candidate gene studies to larger scale genome-wide association studies, meta-analyses and now prospective validation studies. Genotyping is increasingly sophisticated and affordable, and whole-genome sequencing may soon become readily available as a diagnostic tool in the clinic. The ultimate aim of radiogenomics research is to tailor treatment to the individual with a test based on a combination of treatment, clinical and genetic factors. This personalisation would allow the greatest tumour control while minimising acute and long-term toxicity. Here we discuss the evolution of the field of radiogenomics with reference to the most recent developments and challenges.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.clon.2019.02.006en
dc.titleRadiogenomics in the era of advanced radiotherapyen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKen
dc.identifier.journalClinical Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record